Pharmaceutical Composition for Treating Adverse Reactions by Administering Spiegelmers

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes a pharmaceutical composition that uses L-ribozymes—enzymatic RNA molecules made from L-nucleotides—to selectively degrade L-RNA molecules, such as Spiegelmers, when administered therapeutically. Spiegelmers, although considered stable and non-immunogenic, can sometimes cause unexpected side effects or immune reactions. The L-ribozyme acts as an 'antidote' to quickly break down and neutralize the Spiegelmer or other L-RNA molecules in the body, minimizing adverse reactions. Furthermore, the composition can be used to selectively target and degrade endogenous RNAs, including those from overexpressed genes or from pathogens.

Use CasesContent extracted from patent full text and abstract with AI.

• Rapid neutralization of Spiegelmer-based drugs in case of adverse physiological or immunological reactions in patients.
• Controlling and minimizing side effects from therapeutic L-RNA molecules in clinical settings.
• Targeted treatment of diseases associated with overexpression of specific endogenous genes by selectively degrading their mRNAs.
• Potential use in gene therapy to regulate or silence harmful gene products.
• Antiviral, antibacterial, or antifungal therapy by designing ribozymes that target pathogen-specific RNAs.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a highly selective and rapid method to neutralize therapeutically administered Spiegelmers and L-RNAs, improving patient safety.
• Minimizes or prevents side effects and immune responses that could otherwise be caused by persistent L-RNA molecules in the body.
• The ribozyme's high specificity ensures targeted action with minimal impact on non-target RNAs or cellular processes.
• Can be tailored to different RNA targets, making it broadly applicable to various therapeutic and disease scenarios.
• Stable in serum and resistant to degradation, allowing effective delivery and action in the human body.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to the use of an L-ribozyme, which is capable of splitting an L-RNA in the region of a target sequence of the L-RNA, in order to produce a pharmaceutical composition for treating undesired physiological adverse reactions due to the administration of a therapeutic molecule containing the L-RNA. Alternatively, an endogenous target RNA may also be split by the L-ribozyme.